Related Experiment Video
Updated: Oct 31, 2025
08:27
Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
Published on: March 24, 2015
15.0K
HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma
Ying Yang1, Zhuogang Liu1, Hongtao Wang1
1Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China.
Frontiers in Oncology
|June 28, 2021
Summary
Human leukocyte antigen-E (HLA-E) is elevated in multiple myeloma (MM) and linked to advanced disease. This suggests HLA-E is a potential biomarker and therapeutic target for high-risk MM patients.
Area of Science:
- Immunology
- Oncology
Background:
- Human leukocyte antigen-E (HLA-E) plays a role in immune regulation.
- Its involvement in multiple myeloma (MM) pathogenesis is under investigation.
Purpose of the Study:
- To investigate the expression of HLA-E in MM.
- To determine the correlation between HLA-E expression and clinical parameters in MM patients.
- To explore HLA-E as a potential therapeutic target.
Main Methods:
- Quantified HLA-E expression on MM and normal plasma cells.
- Stratified MM patients into high and low HLA-E expression groups.
- Correlated HLA-E expression with International Staging System (ISS) stage and cytogenetic risk stratification using Pearson Chi-square test.
- Assessed the binding affinity of peptide 3 (P3) to HLA-E positive MM cells.
Main Results:
- HLA-E expression was significantly higher in MM cells (39.27 ± 27.01) compared to normal plasma cells (11.28 ± 0.79).
- High HLA-E expression correlated with advanced ISS stage (p = 0.025) and high-risk cytogenetics (p = 0.000).
- Peptide P3 demonstrated high affinity for HLA-E positive MM cells.
Conclusions:
- HLA-E is a potential biomarker for high-risk multiple myeloma.
- HLA-E represents a candidate therapeutic target for MM.
- Peptide P3 shows promise as a targeted therapy for MM cells.
